Pharmafile Logo

News and Press Releases

PEPITEM sequence shows effects in psoriasis, comparable to steroid cream

3 April 2025 -- Birmingham, UK -- Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied topically in an...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 3, 2025

The University of Birmingham
Edgbaston Birmingham, B15 2TT

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia.  3 April...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 3, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research

Initial collaboration will support projects of mutual interest and help accelerate advancement of Astellas’ early-stage oncology pipeline 2 April 2025 -- Tokyo, Japan -- Astellas Pharma Inc and Japanese Foundation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025

Astellas
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

2 April 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: April 2, 2025

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizations Repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025

AC Immune
info@acimmune.com
EPFL Innovation Park-Building B 1015 Lausanne / Switzerland

NICE publishes guidance in England & Wales recommending Altuvoct (efanesoctocog alfa) as a treatment option for people with severe haemophilia A aged 2 years and over

2 April 2025 -- Stockholm, Sweden -- Sobi in the UK today announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England...

Category: Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025

Sobi
info@sobi.com
Norra Stationsgatan 93A Stockholm

Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection

Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 2, 2025

Phesi
info@phesi.com
East Lyme, Connecticut, US

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability Urcosimod stable in single-use ampoules for more than 2½ years FDA requires drug to show...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial Data were...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 29, 2025

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 28, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

WCG ClinSphere Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection

27 March 2025 -- North Carolina, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of WCG ClinSphere™ Total Feasibility's...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025

WCG Clinical
info@wcgclinical.com
212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025

Alys Pharmaceuticals
info@alyspharma.com
100 Northern Avenue Boston Massachusetts 02210, United States

Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25

Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...

Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025

Cleerly
info@cleerlyhealth.com
1099 18th St #2860, Denver, CO 80202

RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib

Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib 26 March 2025 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson &...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 26, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

25 March 2025 -- Massachusetts, US, and Gosselies, Belgium -- iTeos Therapeutics, Inc, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025

iTeos Therapeutics
Bldg 312, Suite 301 Watertown, MA 02472 United States